Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Growth Potential of the Metastatic Prostate Cancer Market Size Over 2025-2034?
The metastatic prostate cancer market size has grown strongly in recent years. It will grow from $8.11 billion in 2024 to $8.81 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to a growing aging population, rising incidence of prostate cancer, increasing awareness and screening programs, improvements in diagnostic techniques and growing healthcare expenditure.
The metastatic prostate cancer market size is expected to see strong growth in the next few years. It will grow to $12.16 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to expanding screening initiatives, favorable reimbursement policies, rising adoption of advanced therapies and market expansion in emerging economies. Major trends in the forecast period include technology advancements in diagnostic imaging, innovations in targeted therapies, developments in liquid biopsy, research and development in immunotherapy and adoption of minimally invasive surgical techniques.
Get your free report sample today:
What Are the Leading Drivers Behind the Growth of the Metastatic Prostate Cancer Market?
The rising demand for personalized treatments is expected to propel the growth of the metastatic prostate cancer market going forward. Personalized treatments refer to medical approaches tailored to an individual’s genetic profile, lifestyle, and specific disease characteristics to achieve more effective and targeted outcomes. The rising demand for personalized treatments is due to the growing availability of genomic profiling and biomarker testing, as these technologies help identify specific mutations and biological markers, allowing clinicians to select therapies that are more likely to be effective for each individual. Personalized treatment approaches, such as biomarker-guided therapies and gene-targeted drugs, are transforming the way metastatic prostate cancer is managed by aligning specific therapies with each patient’s unique tumor profile to improve effectiveness and minimize side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023 compared to 6 in the year 2022. Therefore, the rising demand for personalized treatments is driving the growth of the metastatic prostate cancer market.
Which Market Segment Offers the Most Significant Growth Opportunities in the Metastatic Prostate Cancer Market?
The metastatic prostate cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Immunotherapy, Hormonal Therapy, Radiation Therapy, Other Treatments
2) By Route of Administration: Oral, Parenteral Route, Intravenous, Intrathecal, Intraperitoneal, Intra-Arterial, Topical
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By End User: Hospitals, Clinics, Cancer Centers, Research Laboratories, Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens
2) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine Therapies
3) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors, Combined Androgen Blockade (CAB)
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiotherapy (SBRT), Radiopharmaceutical Therapy, Intensity-Modulated Radiation Therapy (IMRT)
5) By Other Treatments: Targeted Therapy, Bone-Targeted Therapy, Clinical Trial Drugs, Palliative Therapy
Which Disruptive Trends Are Reshaping the Competitive Landscape of the Metastatic Prostate Cancer Market?
Major companies operating in the metastatic prostate cancer market are focusing on developing advanced treatment approaches such as targeted radioligand therapy to enhance treatment specificity, minimize damage to healthy tissues, and improve patient outcomes. Targeted radioligand therapy is an advanced form of precision cancer treatment that combines a molecule designed to target specific cancer cells (ligand) with a radioactive isotope that delivers localized radiation to destroy those cells. For instance, in March 2022, Novartis AG, a Switzerland-based pharmaceuticals and healthcare solutions company, received US Food and Drug Administration (FDA) approval for Pluvicto, the first targeted radioligand therapy for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. It features lutetium-177, a radioactive isotope, linked to a ligand that targets PSMA, a protein found in high levels on prostate cancer cells, enabling precise delivery of radiation. Pluvicto represents a breakthrough in prostate cancer care by significantly extending progression-free survival in patients who have exhausted other treatment options.
Who Are the Top Industry Players Driving the Metastatic Prostate Cancer Market Growth?
Major companies operating in the metastatic prostate cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen Group, Exelixis Inc., Ferring Pharmaceuticals, Dendreon Pharmaceuticals LLC, Hinova Pharmaceuticals Inc., Janux Therapeutics Inc., Zenith Epigenetics Ltd., Tavanta Therapeutics Inc., Cardiff Oncology Inc., Oncternal Therapeutics Inc., Clarity Pharmaceuticals Ltd., Convergent Therapeutics Inc.
Get the detailed metastatic prostate cancer market report today
Which Regional Markets Offer the Most Promising Growth Opportunities for the Metastatic Prostate Cancer Market?
North America was the largest region in the metastatic prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic prostate cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment